The 2023 Evidence-Based Clinical Practice Guideline for Chronic Kidney Disease (CKD) was developed by the Japanese Society of Nephrology. This guideline aims to improve the early detection of CKD, promote collaboration between primary care and specialist physicians, and prevent CKD progression. It also emphasizes the prevention of cardiovascular disease (CVD) and the initiation of dialysis. The guideline was revised to include a more flexible format and to address the needs of both specialist and non-specialist physicians. A new "Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease" was also created to simplify information for primary care physicians. The guideline emphasizes the importance of CKD diagnosis, severity evaluation, and management, including blood pressure control, treatment of proteinuria and albuminuria, and the use of RA system inhibitors. It also provides recommendations for the management of hypertension, diabetes, dyslipidemia, and other comorbidities in CKD patients. The guideline includes detailed recommendations for the management of CKD in different stages, including the use of SGLT2 inhibitors, phosphate binders, and active vitamin D. It also addresses the management of CKD in elderly patients, pregnant women, and patients with kidney transplantation. The guideline emphasizes the importance of individualized treatment, considering the patient's overall health, quality of life, and prognosis. The guideline also provides recommendations for lifestyle modifications, including smoking cessation, alcohol consumption, and exercise. The guideline is supported by a strong evidence base and is intended to guide clinical practice in the management of CKD.The 2023 Evidence-Based Clinical Practice Guideline for Chronic Kidney Disease (CKD) was developed by the Japanese Society of Nephrology. This guideline aims to improve the early detection of CKD, promote collaboration between primary care and specialist physicians, and prevent CKD progression. It also emphasizes the prevention of cardiovascular disease (CVD) and the initiation of dialysis. The guideline was revised to include a more flexible format and to address the needs of both specialist and non-specialist physicians. A new "Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease" was also created to simplify information for primary care physicians. The guideline emphasizes the importance of CKD diagnosis, severity evaluation, and management, including blood pressure control, treatment of proteinuria and albuminuria, and the use of RA system inhibitors. It also provides recommendations for the management of hypertension, diabetes, dyslipidemia, and other comorbidities in CKD patients. The guideline includes detailed recommendations for the management of CKD in different stages, including the use of SGLT2 inhibitors, phosphate binders, and active vitamin D. It also addresses the management of CKD in elderly patients, pregnant women, and patients with kidney transplantation. The guideline emphasizes the importance of individualized treatment, considering the patient's overall health, quality of life, and prognosis. The guideline also provides recommendations for lifestyle modifications, including smoking cessation, alcohol consumption, and exercise. The guideline is supported by a strong evidence base and is intended to guide clinical practice in the management of CKD.